| Not Yet Recruiting | Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) NCT05093972 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants NCT07401862 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations NCT07345689 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 4 |
| Recruiting | A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mi NCT07165002 | Eli Lilly and Company | Phase 1 |
| Recruiting | Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care NCT07343037 | University Hospital, Strasbourg, France | — |
| Completed | A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) NCT07049939 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems NCT06957756 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimina NCT07102095 | Bayer | Phase 1 |
| Recruiting | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With H NCT06858696 | X4 Pharmaceuticals | Phase 1 |
| Completed | A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants NCT06719128 | Eli Lilly and Company | Phase 1 |
| Completed | A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) NCT06575959 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Nor NCT05209295 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function NCT06390410 | Cassava Sciences, Inc. | Phase 1 |
| Unknown | Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride NCT06176716 | Ahon Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency NCT06620731 | Ahon Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of LY3437943 in Participants With Impaired and Normal Liver Function NCT05916560 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of LY3502970 in Participants With Impaired and Normal Liver Function NCT05882032 | Eli Lilly and Company | Phase 1 |
| Completed | A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems NCT05731895 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems NCT05661344 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function NCT05440344 | Eli Lilly and Company | Phase 1 |
| Completed | Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function NCT04993404 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Completed | Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants NCT06190691 | Eli Lilly and Company | Phase 1 |
| Completed | Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases NCT04170309 | Advanz Pharma | — |
| Completed | A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volun NCT04226833 | Hoffmann-La Roche | Phase 1 |
| Completed | Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort NCT04097704 | Celgene | — |
| Completed | A Study of Tirzepatide in Participants With Impaired Liver Function NCT03940742 | Eli Lilly and Company | Phase 1 |
| Completed | Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency NCT04147936 | Axcella Health, Inc | N/A |
| Completed | A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems NCT03842761 | Boehringer Ingelheim | Phase 1 |
| Completed | Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabo NCT03968848 | Acerta Pharma BV | Phase 1 |
| Terminated | Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006) NCT03295266 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Pa NCT03341884 | Genentech, Inc. | Phase 1 |
| Completed | Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency) NCT03306667 | Mochida Pharmaceutical Company, Ltd. | Phase 1 |
| Completed | Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201 NCT02894385 | Bayer | Phase 1 |
| Completed | Major Liver Resection: Early Clotting Disorders and Functional Impairment. NCT02813538 | Hospital General Universitario Gregorio Marañon | — |
| Terminated | Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies NCT02753517 | University Hospital, Lille | N/A |
| Terminated | Mitochondrial Function in Patients With Severe Liver Disease NCT02457702 | University of Texas Southwestern Medical Center | N/A |
| Completed | A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment NCT02387814 | Eli Lilly and Company | Phase 1 |
| Completed | A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 NCT04867941 | Acerta Pharma BV | Phase 1 |
| Completed | Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers NCT02191865 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With M NCT02161224 | Astellas Pharma Europe B.V. | Phase 1 |
| Completed | A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease NCT01870388 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment NCT01836185 | Eli Lilly and Company | Phase 1 |
| Completed | The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009) NCT01797536 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Single Dose Study of LY2605541 in Participants With Liver Impairment NCT01751399 | Eli Lilly and Company | Phase 1 |
| Completed | Extracorporeal Photopheresis After Liver Transplant NCT02090621 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Phase 2 |
| Completed | Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insuf NCT01512693 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of LY2140023 in Hepatically-Impaired Participants NCT01475136 | Denovo Biopharma LLC | Phase 1 |
| Completed | Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Com NCT01860326 | Debiopharm International SA | Phase 1 |
| Completed | Single Dose of 9-cis-retinoic Acid in Hepatic Patients NCT01891526 | University Hospital, Gentofte, Copenhagen | — |
| Completed | A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction NCT01273493 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease NCT01261923 | University Hospital, Gentofte, Copenhagen | Phase 1 / Phase 2 |
| Completed | A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function NCT01186588 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 |
| Completed | Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function NCT01111318 | Boehringer Ingelheim | Phase 1 |
| Completed | Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017) NCT01043926 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) NCT01043887 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032 NCT01019070 | Bristol-Myers Squibb | Phase 1 |
| Completed | Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency NCT00968591 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function NCT00969813 | Pfizer | Phase 1 |
| Completed | Liver Transplantation and Reticuloendothelial Clearance Capacity NCT00929032 | University of Edinburgh | — |
| Completed | Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease NCT00781430 | Puma Biotechnology, Inc. | Phase 1 |
| Unknown | Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT NCT00948558 | Huashan Hospital | — |
| Completed | Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment NCT00859053 | Bristol-Myers Squibb | Phase 1 |
| Completed | Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency an NCT00805090 | Javelin Pharmaceuticals | Phase 1 |
| Completed | Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Com NCT02183376 | Boehringer Ingelheim | Phase 1 |
| Completed | Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics NCT00692341 | Pfizer | Phase 1 |
| Completed | Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimen NCT00645021 | Pfizer | Phase 1 |
| Unknown | Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection NCT00623662 | McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
| Completed | Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subj NCT00931060 | University of Aarhus | N/A |
| Completed | Study of Telaprevir in Subjects With Hepatic Impairment NCT00509210 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Completed | Prognostic Impact of Organ Damage in STEMI Patients NCT02800421 | Inha University Hospital | — |
| Completed | Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function NCT00416702 | Novartis | Phase 1 |
| Completed | Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults NCT00314054 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) NCT02259855 | Boehringer Ingelheim | Phase 1 |
| Completed | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate NCT02170571 | Boehringer Ingelheim | Phase 1 |
| Completed | A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic NCT00144248 | Boehringer Ingelheim | Phase 4 |
| Completed | Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency NCT02249442 | Boehringer Ingelheim | Phase 1 |
| Completed | Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to NCT02265627 | Boehringer Ingelheim | Phase 1 |
| Completed | Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine NCT02184091 | Boehringer Ingelheim | Phase 1 |